Literature DB >> 22253012

JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy.

Serena Delbue1, Francesca Elia, Camilla Carloni, Eleonora Tavazzi, Enrico Marchioni, Silvia Carluccio, Lucia Signorini, Stefano Novati, Renato Maserati, Pasquale Ferrante.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a severe disease of the central nervous system (CNS), caused by infection with the Polyomavirus JC virus (JCV). Because there are no known treatments or prognostic factors, we performed a long-term study focusing mainly on cerebrospinal fluid (CSF) samples from PML patients to describe the virological features akin to the different forms of the disease. Twenty-eight PML patients were enrolled: 10 HIV-1+ patients with classical PML (CPML), 9 HIV-1+ patients with slowly progressing or stable neurological symptoms (benign PML), 3 HIV-1+ asymptomatic patients, and 6 HIV-1-negative patients. CSF, urine, and blood samples were collected at the enrollment (baseline) and every 6 months afterwards when possible. The JCV DNA and HIV-1 RNA loads were determined, and the JCV strains were characterized. At baseline, the mean CSF JCV load was log 6.0 ± 1.2 copies/ml for CPML patients, log 4.0 ± 1.0 copies/ml for benign PML patients, log 4.2 ± 0.5 copies/ml for asymptomatic PML patients, and log 5.8 ± 1.3 copies/ml for HIV-1-negative PML patients (CPML vs. benign: P < 0.01; CPML vs. asymptomatic: P < 0.05; HIV-1 negative vs. benign: P < 0.01). Organization of the JCV transcriptional control region (TCR) showed unusual archetype structures in two long-term survival patients; the NF1 sequence was found most commonly, whereas the Sp1 binding site was the most common for both CPML patients and HIV-1 negative patients. Our results suggest that the JCV load in the CSF and the organization of the TCR should be considered as indicators of PML clinical outcome.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22253012      PMCID: PMC3330164          DOI: 10.1002/jcp.24051

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  36 in total

Review 1.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

2.  Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate.

Authors:  Rainer Gosert; Piotr Kardas; Eugene O Major; Hans H Hirsch
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  Distribution, characterization and significance of polyomavirus genomic sequences in tumors of the brain and its covering.

Authors:  Serena Delbue; Elisabetta Pagani; Franca R Guerini; Cristina Agliardi; Roberta Mancuso; Elisa Borghi; Francesca Rossi; Renzo Boldorini; Claudia Veggiani; Pier Giorgio Car; Pasquale Ferrante
Journal:  J Med Virol       Date:  2005-11       Impact factor: 2.327

4.  A case of a progressive multifocal leukoencephalopathy patient with four different JC virus transcriptional control region rearrangements in cerebrospinal fluid, blood, serum, and urine.

Authors:  Serena Delbue; Giovanni Sotgiu; Daniela Fumagalli; Marilena Valli; Elisa Borghi; Roberta Mancuso; Enrico Marchioni; Renato Maserati; Pasquale Ferrante
Journal:  J Neurovirol       Date:  2005-02       Impact factor: 2.643

5.  Human neurotropic JC virus early protein deregulates glial cell cycle pathway and impairs cell differentiation.

Authors:  A Tretiakova; B Krynska; J Gordon; K Khalili
Journal:  J Neurosci Res       Date:  1999-03-01       Impact factor: 4.164

6.  JC virus type 2B is found more frequently in brain tissue of progressive multifocal leukoencephalopathy patients than in urine from controls.

Authors:  H T Agostini; C F Ryschkewitsch; E J Singer; R W Baumhefner; G L Stoner
Journal:  J Hum Virol       Date:  1998 Mar-Apr

7.  Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy.

Authors:  M A Lima; F Bernal-Cano; D B Clifford; R T Gandhi; I J Koralnik
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-08-14       Impact factor: 10.154

8.  Determinants of survival in progressive multifocal leukoencephalopathy.

Authors:  A Marzocchetti; T Tompkins; D B Clifford; R T Gandhi; S Kesari; J R Berger; D M Simpson; M Prosperi; A De Luca; I J Koralnik
Journal:  Neurology       Date:  2009-11-10       Impact factor: 9.910

9.  Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.

Authors:  Nina Khanna; Luigia Elzi; Nicolas J Mueller; Christian Garzoni; Matthias Cavassini; Christoph A Fux; Pietro Vernazza; Enos Bernasconi; Manuel Battegay; Hans H Hirsch
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

10.  Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.

Authors:  Frederik Neess Engsig; Ann-Brit Eg Hansen; Lars Haukali Omland; Gitte Kronborg; Jan Gerstoft; Alex Lund Laursen; Court Pedersen; Christian Backer Mogensen; Lars Nielsen; Niels Obel
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

View more
  15 in total

1.  A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy.

Authors:  Nobuo Sanjo; Yurie Nose; Yukiko Shishido-Hara; Saneyuki Mizutani; Yoshiki Sekijima; Hitoshi Aizawa; Toru Tanizawa; Takanori Yokota
Journal:  J Neurol       Date:  2018-12-03       Impact factor: 4.849

2.  JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route.

Authors:  Tom Van Loy; Kim Thys; Caroline Ryschkewitsch; Ole Lagatie; Maria C Monaco; Eugene O Major; Luc Tritsmans; Lieven J Stuyver
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  JC virus identified in a patient with persistent and severe West Nile virus disease.

Authors:  Neta S Zuckerman; Victoria Indenbaum; Ron Milo; Ella Mendelson; Yaniv Lustig
Journal:  J Neurovirol       Date:  2019-04-04       Impact factor: 2.643

4.  Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.

Authors:  Paul S Giacomini; Ayal Rozenberg; Imke Metz; David Araujo; Nathalie Arbour; Amit Bar-Or
Journal:  N Engl J Med       Date:  2014-01-30       Impact factor: 91.245

5.  Neuropathology of JC virus infection in progressive multifocal leukoencephalopathy in remission.

Authors:  Karen S SantaCruz; Gulmohor Roy; James Spigel; Elaine L Bearer
Journal:  World J Virol       Date:  2016-02-12

Review 6.  Immune surveillance and response to JC virus infection and PML.

Authors:  Sarah Beltrami; Jennifer Gordon
Journal:  J Neurovirol       Date:  2013-12-03       Impact factor: 2.643

7.  Specific protein profile in cerebrospinal fluid from HIV-1-positive cART-treated patients affected by neurological disorders.

Authors:  Valentina Zanin; Serena Delbue; Annalisa Marcuzzi; Eleonora Tavazzi; Rossella Del Savio; Sergio Crovella; Enrico Marchioni; Pasquale Ferrante; Manola Comar
Journal:  J Neurovirol       Date:  2012-05-12       Impact factor: 2.643

8.  Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Tuan Dong-Si; Sarah Gheuens; Amy Gangadharan; Made Wenten; Jeffrey Philip; James McIninch; Shoibal Datta; Nancy Richert; Carmen Bozic; Gary Bloomgren; Sandra Richman; Thomas Weber; David B Clifford
Journal:  J Neurovirol       Date:  2015-03-14       Impact factor: 2.643

9.  A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes.

Authors:  David B Clifford; Avindra Nath; Paola Cinque; Bruce J Brew; Robert Zivadinov; Leonid Gorelik; Zhenming Zhao; Petra Duda
Journal:  J Neurovirol       Date:  2013-06-04       Impact factor: 2.643

10.  Detection of Malawi polyomavirus sequences in secondary lymphoid tissues from Italian healthy children: a transient site of infection.

Authors:  N Papa; N Zanotta; A Knowles; E Orzan; M Comar
Journal:  Virol J       Date:  2016-06-10       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.